AI integration advances in medical regulation and clinical practice

Regulatory and clinical sectors are increasingly integrating artificial intelligence to advance precision medicine. In the United States, the FDA has released a document regarding the regulation of generative AI medical devices. The agency is considering a competency-based evaluation model, similar to how healthcare professionals are assessed, to address risks associated with evolving algorithms. Additionally, the FDA has established a new Office of Technology and Artificial Intelligence to unify its medical software strategy.

In Spain, the Community of Madrid is developing the ‘Preven-IA’ program. This initiative aims to utilize digital twins—virtual clones created from a patient’s clinical, genomic, and imaging data—to simulate how specific treatments or drugs will affect an individual before they are prescribed. The project also seeks to expand remote monitoring for approximately two million residents living with chronic conditions such as diabetes and hypertension.

On a broader scale, AI is accelerating pharmaceutical research. Insilico Medicine has presented data for rentosertib, a drug developed with AI assistance that targets biological markers of aging. Harvard geneticist David Sinclair has also noted that AI-driven molecular analysis is significantly reducing the time required for complex gene therapy experiments.